A survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries

Chan, Tak Mao; Chapman, Jeremy; Lee, C.J.; Morad, Zaki; Ona, E.T.; Park, K.; Pingle, A.; Rizvi, S. A. H.; Shaheen, Faissal A.M; Sumethkul, V.; Tang, Xiao-Peng; Watarai, Yoshihiko

doi:10.1016/j.transproceed.2004.07.066

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, only 1.4% of patients developed HBV infection, which was in line with the reports from Iran and other countries (18, 33, 36). The incidence of HCV infection was lower than that of other reports (33–35).…”

Section: Discussioncontrasting

confidence: 68%

See 1 more Smart Citation

Infectious complications after kidney transplantation: a single‐center experience

Pourmand

Salem

Mehrsai

et al. 2007

Transplant Infectious Dis

View full text Add to dashboard Cite

Infectious complications after renal transplantation are associated with significant morbidity and mortality. The prevalence of infections in transplant recipients varies from country to country. This study sought to assess the overall incidence of post-transplant infectious complications at our research center in Iran, compared with other centers in the world. Between 2002 and 2004, 179 renal transplantations were performed in our center. Of these, 142 were studied and followed for 1 year. Immunosuppressive regimens were cyclosporine, mycophenolate mofetil, and prednisolone. The overall incidence of infections was 54.2%. The most common sites of infections were the urinary tract (41.5%) and the respiratory tract (6.3%). The most frequent causes of infections were Klebsiella (24%) and cytomegalovirus (CMV) (17.6%). Wound infection occurred in 4.9% of the patients. Three (2.1%) patients developed hepatitis C and 2 (1.4%) had mycobacterial infections. There was no case of Pneumocystis pneumonia. Overall mortality was 7.7%. Infection-related mortality was 3.5%. In conclusion, this study identifies infections as the cause of morbidity and mortality in the post-transplant period. There was a low incidence of tuberculosis (<2% yearly) and a high incidence of CMV disease in our recipients.

show abstract

Section: Discussioncontrasting

confidence: 68%

“…Hepatitis B and C are the major causes of liver disease in transplanted patients (33, 34). In Asian‐Pacific countries, the carrier rate for HBV varies from 1–10%, and from 1–25% in kidney transplant recipients (35). There is a low incidence of HBV and HCV infection in the Iranian population (36).…”

Section: Discussionmentioning

confidence: 99%

Infectious complications after kidney transplantation: a single‐center experience

Pourmand

Salem

Mehrsai

et al. 2007

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…12 Many authors suggested that allocation of renal grafts from donors with HBsAg may be permitted in HBV endemic areas. 12,13 In a recent study, Tuncer and coworkers suggested that HBsAg positivity is not a contraindication for living-donor kidney donation. 5 In summary, when combined with careful HBVmonitoring, renal grafts from HBsAg-positive living …”

Section: Discussionmentioning

confidence: 99%

Living-Donor Kidney Transplant From Hepatitis B Surface Antigen-Positive Donors to Hepatitis B Antibody-Positive Recipients Without Hepatitis B Immunoglobulin Prophylaxis in an Endemic Country

Jun

Kim

Park

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus.

show abstract

“…HBV infection is more frequent in kidney transplant recipients than in the general population mainly due to the high risk of acquisition during dialysis, before kidney transplantation 3 . A survey conducted in 2003 suggests that the HBsAg carrier rate in 11 Asian-Pacific countries ranged from 2 to 10% in patients on peritoneal dialysis, 2 to 20% in patients on hemodialysis, and 1 to 25% in kidney transplant recipients 4 . The etiological factor, kidney transplantation, is further complicated by the use of immunosuppressants which may consequently enhance HBV replication 3 .…”

Section: Introductionmentioning

confidence: 99%

Post-transplant withdrawal of lamivudine results in fatal hepatitis flares in kidney transplant recipients, under immune suppression, with inactive hepatitis B infection

2017

View full text Add to dashboard Cite

Objective: To evaluate the consequences of lamivudine withdrawal in kidney transplant recipients, under immunosuppression, with inactive hepatitis B virus (HBV) infection. Introduction: HBV infection is more frequent in kidney transplant recipients than in the general population mainly due to the high risk of acquisition during dialysis, before kidney transplantation. Methods: The records of hepatitis B surface antigen (HBsAg)-positive, immunosuppressed kidney transplant recipients, where lamivudine was withdrawn after transplantation along with reduction in immunosuppressant dose, admitted to our hospital between 2005 and 2012, were retrospectively evaluated. Discussion: Three patients aged 33, 42 and 33, experienced hepatitis flares 2-3 months after lamivudine withdrawal. Serum HBV DNA levels were 2.5×10 7 , 3.4×10 4 and 4×10 3 IU/ml in cases 1, 2, and 3, respectively. Lamivudine was re-initiated in all cases which led to rapid viral suppression. However, liver function continued to deteriorate leading to severe jaundice, coagulopathy and encephalopathy. All patients died of acute liver failure within six months after the onset of withdrawal hepatitis. Conclusion: Lamivudine should be continued as long as immunosuppressive therapy lasts.

show abstract

A survey on the prevalence and management of hepatitis B after renal transplantation in Asian-Pacific countries

Cited by 7 publications

References 0 publications

Infectious complications after kidney transplantation: a single‐center experience

Infectious complications after kidney transplantation: a single‐center experience

Living-Donor Kidney Transplant From Hepatitis B Surface Antigen-Positive Donors to Hepatitis B Antibody-Positive Recipients Without Hepatitis B Immunoglobulin Prophylaxis in an Endemic Country

Post-transplant withdrawal of lamivudine results in fatal hepatitis flares in kidney transplant recipients, under immune suppression, with inactive hepatitis B infection

Contact Info

Product

Resources

About